NDAINTRAMUSCULARINJECTABLE
Approved
Oct 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUNELLE is a monthly intramuscular injectable contraceptive combining estradiol cypionate and medroxyprogesterone acetate. It provides hormonal contraception through a combination of estrogen and progestin delivered via injection. The product is indicated for prevention of pregnancy in women of reproductive age.
LOE Approaching
LOE-approaching product with moderate competitive pressure (30/100) suggests declining team investment and potential headcount reductions in coming years.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LUNELLE offers limited career growth given its LOE-approaching status and minimal linked job openings; roles focus on managing decline and maximizing remaining market value. This is a defensive commercial position better suited to early-career consolidation or transition-focused roles rather than growth-trajectory advancement.
Brand ManagerField Sales Representative
Worked on LUNELLE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.